Manufacturing: Page 2
-
Stock via Getty Images
OpinionThe 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences
A preview of the top trends on the minds of industry and market leaders for the new year.
By Taren Grom • Jan. 3, 2023 -
Permission granted by CSL
Q&AA historic approval could transform CSL from being ‘the biggest company no one has ever heard of’
The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug.
By Meagan Parrish • Dec. 6, 2022 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Amornrat Phuchom via Getty Images
While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help
Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.
By Michael Gibney • Nov. 8, 2022 -
Sean Gallup / Staff via Getty Images
How Europe’s energy crisis is impacting pharma
Inflationary pressures and rising energy costs could further expedite the movement of generics manufacturing from Europe to Asia if governments don’t step in.
By Karissa Waddick • Nov. 2, 2022 -
Permission granted by Phil Inc.
Sponsored by Phil, Inc.Developing a channel strategy that optimizes gross to net
Today, pharma manufacturers face unprecedented GTN challenges. To unlock sustainable brand growth, a value-aligned channel strategy is pivotal.
Oct. 31, 2022 -
Permission granted by Doug Langa
Backed by celebrity interest, Novo is finding new success in weight loss — while staying true to its roots
The company's head of U.S. and Canadian operations explains how it’s evolving its game plan after 100 years in the insulin space.
By Meagan Parrish • Oct. 25, 2022 -
Stock via Getty Images
5 impactful drug trial failures from the last year
Major recent trial flops and what they mean for companies, patients and the industry.
By Meagan Parrish • Oct. 19, 2022 -
iStock via Getty Images
Making MovesC-suite shake-ups at 23andMe, Moderna signal new stages of growth
With their latest personnel moves, these life sciences companies are preparing for major business shifts.
By Karissa Waddick • Oct. 5, 2022 -
Stock via Getty Images
Q&AIt’s electric — speeding up the cell therapy process for scalability
To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.
By Alexandra Pecci • Oct. 4, 2022 -
Md Saiful Islam Khan via Getty Images
Feds could soon bring COVID-style fight to superbug threat
COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.
By Karissa Waddick • Sept. 13, 2022 -
Stock via Getty Images
4 ways to nail the launch of your cell therapy
A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.
By Meagan Parrish • Aug. 10, 2022 -
Mario Tama via Getty Images
The ‘alarming’ spread of Monkeypox — by the numbers
With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’
By Meagan Parrish • Aug. 8, 2022 -
Ivan Balvan via Getty Images
Making MovesEditas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires
How these latest executive personnel changes are impacting the industry.
By Karissa Waddick • Aug. 3, 2022 -
Permission granted by Catherine Owen.
Q&AA glimpse inside Bristol Myers Squibb’s integration with Celgene
Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.
By Meagan Parrish • Aug. 1, 2022 -
Permission granted by John LaMattina
Pfizer's former R&D head takes on drug pricing misconceptions in new book
John LaMattina has something to say about the industry — and he hopes patients are listening.
By Meagan Parrish • July 19, 2022 -
Stock via Getty Images
Q&A // First 90 DaysAnjarium Biosciences’ CEO on its next-gen gene therapies
Stephen Yoo aims to build on the buzz around the company’s leading-edge gene therapy tech.
By Kim Ribbink • July 15, 2022 -
Stock via Getty Images
Q&AThe CEO of Dr. Reddy's N. America is using 'controlled explosions' to keep the generics giant growing
Marc Kikuchi weighs in on the company’s plans to pump up its pipeline and sales in the coming years.
By Meagan Parrish • July 7, 2022 -
Permission granted by David Ross/Seqirus.
Dave Ross of Seqirus talks 'milestone' influenza vax vote
In a unanimous decision, a CDC committee calls for a preferential flu vaccine recommendation for people aged 65 and older for the first time.
By Alexandra Pecci • July 5, 2022 -
Stock via Getty Images
Q&A // Biotech SpotlightBiotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform
As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.
By Kim Ribbink • June 30, 2022 -
iStock via Getty Images
Q&AWhy biomanufacturing is the next innovation frontier for genomic therapies
While cell and gene therapy research has accelerated quickly, manufacturing in the space hasn’t quite kept up, Danaher’s Chief Science Officer JC Gutiérrez-Ramos says.
By Meagan Parrish • June 13, 2022 -
Stock via Getty Images
SIGA prepares to kick production for monkeypox treatment into high gear
‘We’re not bored,’ the company’s science chief says as SIGA Technologies looks to ramp up supplies of its therapeutic.
By Meagan Parrish • May 31, 2022 -
John Moore via Getty Images
A potential COVID-19 EUA could turn this small biotech into a household name
Veru’s CEO discusses the impact of the upcoming FDA decision on its treatment targeting severely ill COVID-19 patients.
By Meagan Parrish • May 19, 2022 -
Natali_Mis via Getty Images
Q&A // Biotech SpotlightBiotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach
Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.
By Michael Gibney • May 17, 2022 -
Stock via Getty Images
Q&A // Biotech SpotlightBiotech Spotlight: Everest Medicines takes aim at unmet needs in Asia
With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.
By Taren Grom • May 9, 2022 -
Adobe Stock / Song about summer
Sponsored by EVERSANARight-sizing the channel strategy for maximum impact
Failure to right-size your distribution model imposes financial penalties and wasted expenditures.
May 9, 2022
Previous
